204 related articles for article (PubMed ID: 25412857)
1. High-risk HPV platforms and test of cure: should specific HPV platforms more suited to screening in a 'test of cure' scenario be recommended?
Innamaa A; Dudding N; Ellis K; Crossley J; Smith JH; Tidy JA; Palmer JE
Cytopathology; 2015 Dec; 26(6):381-7. PubMed ID: 25412857
[TBL] [Abstract][Full Text] [Related]
2. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
[TBL] [Abstract][Full Text] [Related]
3. Does LLETZ excision margin status predict residual disease in women who have undergone post-treatment cervical cytology and high-risk human papillomavirus testing?
Palmer JE; Ravenscroft S; Ellis K; Crossley J; Dudding N; Smith JH; Tidy JA
Cytopathology; 2016 Jun; 27(3):210-7. PubMed ID: 26415635
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the performance of HPV tests in women with abnormal cytology: results of a study within the NHS cervical screening programme.
Moss SM; Bailey A; Cubie H; Denton K; Sargent A; Muir P; Vipond IB; Winder R; Kitchener H
Cytopathology; 2015 Dec; 26(6):373-80. PubMed ID: 25274541
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
8. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C
J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930
[TBL] [Abstract][Full Text] [Related]
9. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
11. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
12. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.
Cook DA; Mei W; Smith LW; van Niekerk DJ; Ceballos K; Franco EL; Coldman AJ; Ogilvie GS; Krajden M
BMC Cancer; 2015 Dec; 15():968. PubMed ID: 26674353
[TBL] [Abstract][Full Text] [Related]
14. Risk of cervical high-grade squamous intraepithelial neoplasia in cytologic negative and persistently high-risk human papillomavirus positive patients according to genotypes: a retrospective single center analysis.
Kipp B; Ulrich E; van Meegen C; Schwenzer T
BMC Infect Dis; 2024 Jun; 24(1):558. PubMed ID: 38834951
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
16. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
17. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Clinical Performance of Aptima HPV Assay and the Cobas 4800 Platform in Women with Normal Cytology and Positive High-Risk HPV.
Kir G; Dokmeci Guney D; Seneldir H
Acta Cytol; 2023; 67(4):395-402. PubMed ID: 36977394
[TBL] [Abstract][Full Text] [Related]
19. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test.
van der Heijden E; Lopes AD; Bryant A; Bekkers R; Galaal K
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010757. PubMed ID: 25562623
[TBL] [Abstract][Full Text] [Related]
20. Immediate histologic correlation in women with atypical squamous cells of undetermined significance cytology and positive high-risk HPV: A retrospective review of 6000 cases in a large academic women's hospital.
Zhang H; Pradhan D; Wang T; Ashman D; Matsko J; Zhao C
Cancer Cytopathol; 2020 Nov; 128(11):852-859. PubMed ID: 32639689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
